Effect of ursodeoxycholic acid (150 mg/kg, p.o.) and fenofibrate (100 mg/kg, p.o.) on body weight, serum parameters and blood pressure in rats administered fructose. by Amr A. A. Mahmoud (627688)

Fig 5 - by Te-Hsing Hsu (16973374)

RUE decreases the level of alcohol-induced liver damage markers. by Jeong Hoon Pan (844624)

Bortezomib decreases intracellular viral RNA. by Moushimi Amaya (524600)

Fig 5 - by Lingru Ruan (18995544)

MVK activates microglia and decreases phagocytosis. by Ren Y. Sato (16914027)

PDE-5 inhibition with sildenafil decreases the amount of dipropylenetriamine NONOate (DPTA-NO) necessary to prevent ECM. by Yuri C. Martins (333396)

Rabankyrin-5 Overexpression Increases, whereas Knock-Down Decreases Fluid-Phase Uptake, Specifically by Carsten Schnatwinkel (48)

The antinociceptive effects produced by the intraperitoneal administration of CoPP at 5 and 10 mg/kg in STZ injected mice. by Sílvia Castany (843274)

Fig 5 - by Elizabeth A. Moore (18083377)

Subjects:

Fig 5 - by Shivankar Agrawal (11565095)

Expressions of core UPR^mt proteins following PM2.5 exposure. by Cao Wang (1500691)

Subjects:

Combination treatment decreased PI3K/Akt/mTOR pathways more efficiently than SLCP or BBR treatments alone. by Panchanan Maiti (1459852)

Decreased chymotrypsin-like activity of proteasomes in U87MG cells that express PTEN. by Rajaa Errafiy (497050)

Five-hours-old clots were subjected to scanning electron microscopy. by Jan Víteček (11434774)

Effect of ursodeoxycholic acid (150 mg/kg, p.o.) and fenofibrate (100 mg/kg, p.o.) on aortic malondialdehyde (MDA) content (a) and aortic reduced glutathione (GSH) content (b) in f... by Amr A. A. Mahmoud (627688)

Piceatannol decreases renal fibrosis in the UUO kidney. by Sin Young Choi (3370778)

JBPOS0101 decreased Amyloid Beta (Aβ) aggregates in the cortex and hippocampal regions in 5xFAD mouse brains. by Jihoon Jeong (4852690)

Metformin pre-treatment retains an antioxidant effect and decreases apoptosis, in an AMPK activation manner. by Silvia Siteni (10344070)

Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5‑ASA–PABA–MAC and 5‑ASA–PABA–Diamine for the T... by Jiaxing Zhao (3965057)

“…To mitigate the systemic adverse effects of tofacitinib, 5-ASA–PABA–MAC and 5-ASA–PABA–diamine colon-specific delivery systems were constructed, and tofacitinib azo prodrugs <b>9</b> and <b>20a–20g</b> were synthesized accordingly. …”